Poolbeg Pharma PLC (POLB.L)

13,00 -0,05 (-0,38%) Alla chiusura: 03:47PM BST

Poolbeg Pharma PLC

Queen Mary BioEnterprises Innovation Centre
42 New Road
London E1 2AX
United Kingdom
44 20 7183 1499
https://www.poolbegpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 15

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Cathal Martin Friel	Executive Chairman of The Board	150k	N/D	1964
Dr. Jeremy Skillington Ph.D.	CEO & Director	362k	N/D	1971
Mr. Ian O'Connell	CFO & Director	237k	N/D	1987
Carol Dalton	Vice President of Investor Relations & Public Relations	N/D	N/D	N/D
Mr. John McEvoy	Senior Vice President & Chief Legal Officer	N/D	N/D	N/D
Mr. David James Allmond	Chief Business Officer	N/D	N/D	1970
Mr. Ross Crockett	Group Financial Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Poolbeg Pharma PLC al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.